Sun Pharma will be in focus after reporting a Q2 FY26 net profit of Rs 3,117.95 crore, up 2.6% YoY, with revenue rising 8.6% to Rs 14,405 crore. Innovative Medicines drove growth, surpassing U.S. generics for the first time. EBITDA rose 14.9% with strong margins. Nuvama maintained a ‘Hold’ rating, citing competition risks and potential U.S. policy headwinds.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets